Copyright © 2014 University of York.
Bookshelf ID: NBK184742
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].
Show detailsBibliographic details: Aljumah AA, Murad MH. Pegylated versus standard interferon plus ribavirin in chronic hepatitis C genotype 4: a systematic review and meta-analysis. Hepatology Research 2013; 43(12): 1255-1263. [PubMed: 23458104]
Abstract
AIM: Treatment of hepatitis C genotype 4 (HCV-G4) with pegylated interferon (PEG IFN) has not been adequately studied and is considered to be challenging. The aim of this meta-analysis is to systematically review and evaluate the effectiveness of 48 weeks of combined PEG IFN plus ribavirin (RBV) compared to standard interferon (IFN) plus RBV. The outcome of interest is sustained virological response (SVR).
METHODS: We searched for eligible randomized controlled trials (RCT) through May 2012. Random effects meta-analysis was used to pool the risk ratio (RR) of achieving SVR across trials.
RESULTS: Five RCT enrolling 386 patients were included. The PEG IFN/RBV group had increased likelihood of achieving SVR (RR = 1.51, 95% confidence interval [CI] = 1.08-2.10). SVR was significantly higher in PEG IFN-α-2a compared to the -α-2b group (P = 0.02). There was no statistically significant effect of ribavirin dosage on SVR (P = 0.55). The quality of evidence was moderate overall and limited by heterogeneity.
CONCLUSION: In treatment-naive patients with HCV-G4, treatment with PEG IFN plus RBV achieves higher SVR rate than treatment with IFN plus RBV.
© 2013 The Japan Society of Hepatology.
- Review Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.[Health Technol Assess. 2004]Review Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Health Technol Assess. 2004 Oct; 8(39):iii-iv, 1-125.
- Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.[PLoS One. 2015]Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.Macías J, López-Cortés LF, Téllez F, Recio E, Ojeda-Burgos G, Ríos MJ, Rivero-Juárez A, Delgado M, Rivas-Jeremías, Pineda JA. PLoS One. 2015; 10(12):e0143492. Epub 2015 Dec 7.
- Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3.[Braz J Infect Dis. 2012]Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3.Vigani AG, Gonçales ES, Pavan MH, Genari F, Tozzo R, Lazarini MS, Fais V, Feltrin A, Gonçales NS, Gonçales FL Jr. Braz J Infect Dis. 2012 May-Jun; 16(3):232-6.
- Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.[Enferm Infecc Microbiol Clin. ...]Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.Macías J, Rivero A, Cifuentes C, Camacho A, Neukam K, Rivero-Juárez A, Mira JA, Torre-Cisneros J, Gómez-Mateos J, Pineda JA. Enferm Infecc Microbiol Clin. 2013 Aug-Sep; 31(7):424-9. Epub 2013 Feb 28.
- Review Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.[Health Technol Assess. 2007]Review Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N. Health Technol Assess. 2007 Mar; 11(11):1-205, iii.
- Pegylated versus standard interferon plus ribavirin in chronic hepatitis C genot...Pegylated versus standard interferon plus ribavirin in chronic hepatitis C genotype 4: a systematic review and meta-analysis - Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews
Your browsing activity is empty.
Activity recording is turned off.
See more...